Here are four things to know:
1. The company surpassed its goal of $1.5 million in the funding round.
2. The funding comes weeks before the company’s anticipated launch date for its magnesium-based bone void filler product, OsteoCrete.
3. OsteoCrete is resorbable, injectable, moldable, osteoconductive and nontoxic.
4. The FDA cleared the product for long-bone and general orthopedic applications.
More articles on devices:
Histogenics acquires sole development, marketing rights for NeoCart in Japan: 5 key notes
Study: Cartiva SCI an effective for toe osteoarthritis treatment — 4 points
Medtronic invests in Mazor, inks commercial agreement: 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
